Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III study of Vical's HSV-2 therapeutic vaccine does not meet primary endpoint

June 12, 2018

HIV-1 fusion peptide targeting, a promising vaccination strategy eliciting neutralizing antibodies

June 12, 2018

New Dong-A compound shows activity against resistant Gram-negative bacteria

June 12, 2018

XORTX files FDA pre-IND meeting request letter

June 12, 2018

FDA grants orphan drug designation to LK-01 for the treatment of AML

June 12, 2018

FDA clears IND for phase I trial of CK-0801 for bone marrow failure syndromes

June 11, 2018

SHP2, a potential therapeutic target in KRAS-mutant tumors

June 11, 2018

Taiho studies TAS-0728 in solid tumors with HER2 or HER3 abnormalities

June 11, 2018

Pfizer initiates phase II study of PF-06730512 in primary focal segmental glomerulosclerosis

June 11, 2018

NeuroVia initiates phase I/II trial of NV-1205 in childhood cerebral adrenoleukodystrophy

June 11, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...